AVDL News and Press, Avadel Pharmaceuticals plc From 03/21/22

We are initiating AVDL at a speculative buy rating, with a target price of USD 14. We like AVDL's lead candidate FT218, and we believe the upcoming PDUFA on March 31st to be the critical catalyst for the company. We believe AVDL will be able to generate USD ~300M peak sales. ...

Avadel Pharmaceuticals plc (AVDL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 A.M. ET Company Participants Brandi Robinson - Senior Vice President, Corporate Affairs Gregory Divis - Chief Executive Officer Douglas Williamson - Chief Medical Officer Tom McHugh - Chief Financial Office...

Avadel Pharmaceuticals press release (NASDAQ:AVDL): Q4 GAAP EPS of -$0.38 beats by $0.03. Cash, cash equivalents and marketable securities were $157.2 million as of December 31, 2021. For further details see: Avadel Pharmaceuticals GAAP EPS of -$0.38 beats by $0.03

FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launch Expanded the robust portfolio of data supporting the potential impact of FT218 on people living with narcolepsy with multiple presentations at...

ACN,ALDX,AVDL,OTCQX:AYRWF,CMC,CSIQ,DBI,DG,DXLG,OTCQX:EDVMF,GIII,HUT,IMV,KIRK,LICY,LQDA,MDWD,OTCQX:NLCP,OTCPK:PNGAY,RDHL,SIG,SYBX,OTCPK:VEOEY,XNET,ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. ...

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 17, 2022, to provide a corpo...

On Friday, the clinical-stage pharma company, Avadel Pharmaceuticals (NASDAQ:AVDL) announced additional data for the company’s lead asset FT218 from a pivotal late-stage trial and an open-label study. FT218 is a formulation of sodium oxybate designed as a once-nightly regimen for exces...

Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly preferred over twice-nightly dosing Post-hoc analyses support positive results observed...

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at th...